by Maria Zannes | Dec 5, 2024 | Press Releases
SAN ANTONIO, TX (Dec. 5, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, will join Federal Supply System (FSS) officials today in a joint...
by Maria Zannes | Nov 14, 2024 | Press Releases
bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024 Expanded CyPath® Lung test sales to physicians in Illinois, Alabama, and Louisiana; now receiving orders from physicians in 11 states Number of physician offices signed increased 75% over Q2 2024...
by Maria Zannes | Nov 4, 2024 | Press Releases
Dr. William Bauta, bioAffinity Senior Vice President of Research and Development and former Associate Director of Science at Genzyme and Ilex, steps into new role with the retirement of Dr. Vivienne Rebel SAN ANTONIO, Texas (Nov. 4, 2024) – bioAffinity Technologies,...
by Maria Zannes | Oct 30, 2024 | Press Releases
SAN ANTONIO, Texas (Oct. 30, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage lung cancer and other lung diseases, today announced that the Japan Patent...
by Maria Zannes | Oct 18, 2024 | Press Releases
SAN ANTONIO, TX (Oct. 18, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced it has entered into a securities purchase agreement with...
by Maria Zannes | Oct 16, 2024 | Press Releases
bioAffinity VP served on expert panel that published new guidance SAN ANTONIO, TX (Oct. 16, 2024) – bioAffinity Technologies’ (Nasdaq: BIAF) Vice President of Diagnostics, Jennifer Rebeles, Ph.D., was part of a panel of worldwide experts that published the...
